TrialAnnals of the rheumatic diseases2025

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial.

D Ware Branch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.